Alexander C. Ford
Ford, Alexander C.
VIAF ID: 315208922 (Personal)
Permalink: http://viaf.org/viaf/315208922
Preferred Forms
- 100 0 _ ‡a Alexander C. Ford
- 100 1 _ ‡a Ford, Alexander C.
-
-
- 100 1 _ ‡a Ford, Alexander C.
4xx's: Alternate Name Forms (7)
Works
Title | Sources |
---|---|
Czy w podstawowej opiece zdrowotnej powinniśmy stosować w świeżej dyspepsji leczenie intensyfikowane czy redukowane? | |
GI epidemiology, 2013: | |
Polyethylene glycol in constipation-predominant irritable bowel syndrome. | |
Poor predictive value of lower gastrointestinal alarm features in the diagnosis of colorectal cancer in 1981 patients in secondary care | |
The possible risks of proton pump inhibitors | |
Predicting Response to Rifaximin in Irritable Bowel Syndrome with Diarrhea: Is the Answer Blowing in the Wind? | |
Prevalence of, and predictors of, bile acid malabsorption in outpatients with chronic diarrhea. | |
Prevalence of functional gastrointestinal disorders among consecutive new patient referrals to a gastroenterology clinic | |
Prevalence of organic disease at colonoscopy in patients with symptoms compatible with irritable bowel syndrome: cross-sectional survey | |
Prevalence of uninvestigated dyspepsia 8 years after a large waterborne outbreak of bacterial dysentery: a cohort study | |
Proton pump inhibitors and oesophageal cancer: Flawed methodology and false alarms. | |
Psychological Comorbidity and Inflammatory Bowel Disease Activity: Cause or Effect? | |
Rates of upper gastrointestinal endoscopy and gastro-oesophageal malignancy outcomes | |
Reactive Versus Proactive Therapeutic Drug Monitoring in Inflammatory Bowel Disease Patients Treated With Infliximab: A Self-Fulfilling Prophecy. | |
Reducing the need for random colonic biopsies in patients with diarrhea. | |
Redundant Data in the Meta-analysis onHelicobacter pyloriEradication | |
The relationship between different information sources and disease-related patient knowledge and anxiety in patients with inflammatory bowel disease. | |
Renzapride in IBS: is efficacy in the eye of the beholder? | |
Reply to Akobeng | |
Reply to Machicado JD, Villafuerte-Galvez J, Marcos LA, Prevalence of irritable bowel syndrome in South America | |
Reporting of relapse rates in a trial of mesalazine for ulcerative colitis | |
Response to Doherty and Moss | |
Response to Levenstein and Prantera. | |
Response to Yang et al | |
Safety of Adding Oats to a Gluten-Free Diet for Patients With Celiac Disease: Systematic Review and Meta-analysis of Clinical and Observational Studies. | |
Screening for bile acid diarrhoea in suspected irritable bowel syndrome. | |
The Short-Form Leeds Dyspepsia Questionnaire validation study. | |
Should we step-up or step-down in the treatment of new-onset dyspepsia in primary care? | |
Simple Clinical Colitis Activity Index: Accurate Assessment of Inflammatory Burden or Reflection of Low Mood and Somatoform Behavior? | |
Sporadic duodenal adenoma and colorectal neoplasia. | |
Stool as a treatment for IBS: more questions than answers? | |
Symbiotics in irritable bowel syndrome--better than probiotics alone? | |
Systematic review: granulocyte/monocyte adsorptive apheresis for ulcerative colitis | |
Systematic review: prognostic tests of paracetamol-induced acute liver failure. | |
Systematic review: the effects of fibre in the management of chronic idiopathic constipation | |
Systematic review: The epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. | |
Systematic review with meta-analysis: malignancies with anti-tumour necrosis factor-α therapy in inflammatory bowel disease. | |
Systematic review with meta-analysis: the effect of tobacco smoking on the natural history of ulcerative colitis. | |
Treatment of Helicobacter pylori in Latin America | |
Treatment of irritable bowel syndrome: beyond fiber and antispasmodic agents | |
Use of Biomarkers in Irritable Bowel Syndrome: To Predict the Future, Look at the Past | |
Use of Probiotics in Hospitalized Adults to Prevent Clostridium difficile Infection: DownGRADE the Quality of Evidence? | |
Utility of Fecal Calprotectin in Differentiating Active Inflammatory Bowel Disease From Coexistent Irritable Bowel Syndrome | |
Utility of the Oral Capsaicin Test in Diagnosing Functional Dyspepsia | |
Validation and modification of a diagnostic scoring system to predict microscopic colitis | |
Validation of a Serum Biomarker for Irritable Bowel Syndrome: Is an Accurate, Single Biomarker Test Possible? | |
Validation of the Rome III criteria for the diagnosis of irritable bowel syndrome in secondary care | |
VSL#3 and Remission in Active Ulcerative Colitis: Larger Studies Required | |
VSL#3 in Postoperative Crohn’s Disease | |
What is the prevalence of clinically significant endoscopic findings in subjects with dyspepsia? Systematic review and meta-analysis | |
Who consults with dyspepsia? Results from a longitudinal 10-yr follow-up study | |
Whom should we "test and treat" for Helicobacter pylori? | |
Will the history and physical examination help establish that irritable bowel syndrome is causing this patient's lower gastrointestinal tract symptoms? | |
World Gastroenterology Organisation Global Guidelines: GERD Global Perspective on Gastroesophageal Reflux Disease. | |
Yield of diagnostic tests for celiac disease in individuals with symptoms suggestive of irritable bowel syndrome: systematic review and meta-analysis | |
Young GI angle: How to approach evidence-based medicine | |
প্রত্যুত্তর |